Bronnen:
Saura C, de Azambuja E, Hlauschke D, et al. Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC). ESMO 2017 Congress; abstract LBA10_PR.
Saura C, de Azambuja E, Hlauschke D, et al. Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC). ESMO 2017 Congress; abstract LBA10_PR.